There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

The average age for someone diagnosed with Kidney Cancer in the U.S. is 65. But one local man’s decades-long battle with ...

These findings should inform public health policies aimed at guaranteeing access to effective combination therapies. Renal cell carcinoma (RCC) is one of the most common malignancies of the ...

Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia A retrospective study was ...

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate ...

Background: Thioredoxin reductase (Trx) has been implicated in activation of hypoxia-inducible factor-1α, which is overexpressed in > 85% of renal cell carcinomas (RCCs). We evaluated the safety ...